PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The new patents cover critical advancements in cochlear implant technology
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
Subscribe To Our Newsletter & Stay Updated
